Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview
Changjin Wu, Wentan Li, Hongyu Tao, Xiyan Zhang, Xin Yu, Ruomeng Song, Kaige Wang, Ling Zuo, Yuanyi Cai, Huazhang Wu, Wen Hui
Topics & Concepts
AtezolizumabPembrolizumabNivolumabMedicineIpilimumabDurvalumabOncologyLung cancerCost effectivenessInternal medicineImmunotherapyCancerRisk analysis (engineering)Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentImmunotherapy and Immune Responses